Recent Research Analysts’ Ratings Changes for Centene (CNC)

A number of research firms have changed their ratings and price targets for Centene (NYSE: CNC):

• 7/29/2026 – Centene was given a new $66.00 price target by Morgan Stanley.
• 7/29/2026 – Centene had its “overweight” rating reaffirmed by Barclays PLC. They now have a $80.00 price target on the stock, up from $75.00.
• 7/29/2026 – Centene was upgraded by Zacks Research from “hold” to “strong-buy”.
• 7/29/2026 – Centene had its price target raised by Robert W. Baird from $46.00 to $66.00. They now have a “neutral” rating on the stock.
• 7/18/2026 – Centene was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 7/17/2026 – Centene had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 7/14/2026 – Centene had its “hold” rating reaffirmed by TD Cowen. They now have a $65.00 price target on the stock, up from $47.00.
• 7/14/2026 – Centene had its price target raised by Truist Financial Corporation from $71.00 to $78.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Centene was given a new $69.00 price target by Wells Fargo & Company. They now have an “equal weight” rating on the stock.
• 7/9/2026 – Centene had its price target raised by Royal Bank Of Canada from $70.00 to $71.00. They now have a “sector perform” rating on the stock.
• 7/7/2026 – Centene was given a new $75.00 price target by Raymond James Financial, Inc..
• 7/7/2026 – Centene had its price target raised by Cantor Fitzgerald from $60.00 to $75.00. They now have an “overweight” rating on the stock.
• 6/29/2026 – Centene was downgraded by Zacks Research from “strong-buy” to “hold”.
• 6/23/2026 – Centene is now covered by Royal Bank Of Canada. They set a “sector perform” rating and a $70.00 price target on the stock.
• 6/16/2026 – Centene had its “overweight” rating reaffirmed by Barclays PLC.
• 6/11/2026 – Centene had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 6/8/2026 – Centene was given a new $63.00 price target by Mizuho. They now have a “neutral” rating on the stock.
• 6/8/2026 – Centene had its price target raised by JPMorgan Chase & Co. from $52.00 to $60.00. They now have a “neutral” rating on the stock.
• 6/4/2026 – Centene had its price target raised by Bank of America Corporation from $72.00 to $74.00. They now have a “buy” rating on the stock.
• 6/4/2026 – Centene had its price target raised by Morgan Stanley from $50.00 to $57.00. They now have an “equal weight” rating on the stock.
• 6/1/2026 – Centene had its price target raised by Truist Financial Corporation from $58.00 to $71.00. They now have a “buy” rating on the stock.

Centene Corporation (NYSE: CNC) is a diversified, multi-national healthcare enterprise that specializes in providing services to government-sponsored and national health programs. The company primarily acts as a managed care organization, delivering healthcare coverage and administering benefits for Medicaid, the Children’s Health Insurance Program (CHIP), Medicare Advantage, and individual marketplace plans. Centene also contracts with federal and state agencies to manage specialty care programs and community-based services for vulnerable populations.

Centene’s offerings extend beyond traditional insurance to include a range of specialty and support services.